Medifast Statistics
Total Valuation
Medifast has a market cap or net worth of $126.42 million. The enterprise value is -$25.43 million.
| Market Cap | 126.42M |
| Enterprise Value | -25.43M |
Important Dates
The last earnings date was Monday, October 26, 2026, before market open.
| Earnings Date | Oct 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Medifast has 10.40 million shares outstanding. The number of shares has increased by 0.94% in one year.
| Current Share Class | 10.40M |
| Shares Outstanding | 10.40M |
| Shares Change (YoY) | +0.94% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 3.59% |
| Owned by Institutions (%) | 63.93% |
| Float | 8.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.42 |
| Forward PS | 0.46 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.11.
| Current Ratio | 4.82 |
| Quick Ratio | 4.12 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -20.69% and return on invested capital (ROIC) is -84.22%.
| Return on Equity (ROE) | -20.69% |
| Return on Assets (ROA) | -8.56% |
| Return on Invested Capital (ROIC) | -84.22% |
| Return on Capital Employed (ROCE) | -17.58% |
| Weighted Average Cost of Capital (WACC) | 6.96% |
| Revenue Per Employee | $788,347 |
| Profits Per Employee | -$107,505 |
| Employee Count | 380 |
| Asset Turnover | 1.18 |
| Inventory Turnover | 4.15 |
Taxes
In the past 12 months, Medifast has paid $11.70 million in taxes.
| Income Tax | 11.70M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.25% in the last 52 weeks. The beta is 0.70, so Medifast's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | -0.25% |
| 50-Day Moving Average | 11.99 |
| 200-Day Moving Average | 11.32 |
| Relative Strength Index (RSI) | 54.27 |
| Average Volume (20 Days) | 132,298 |
Short Selling Information
The latest short interest is 1.16 million, so 11.13% of the outstanding shares have been sold short.
| Short Interest | 1.16M |
| Short Previous Month | 1.86M |
| Short % of Shares Out | 11.13% |
| Short % of Float | 13.58% |
| Short Ratio (days to cover) | 9.59 |
Income Statement
In the last 12 months, Medifast had revenue of $299.57 million and -$40.85 million in losses. Loss per share was -$3.69.
| Revenue | 299.57M |
| Gross Profit | 207.33M |
| Operating Income | -34.78M |
| Pretax Income | -29.15M |
| Net Income | -40.85M |
| EBITDA | -22.03M |
| EBIT | -34.78M |
| Loss Per Share | -$3.69 |
Balance Sheet
The company has $172.53 million in cash and $20.69 million in debt, with a net cash position of $151.85 million or $14.59 per share.
| Cash & Cash Equivalents | 172.53M |
| Total Debt | 20.69M |
| Net Cash | 151.85M |
| Net Cash Per Share | $14.59 |
| Equity (Book Value) | 180.28M |
| Book Value Per Share | 17.33 |
| Working Capital | 160.06M |
Cash Flow
In the last 12 months, operating cash flow was -$26,000 and capital expenditures -$3.84 million, giving a free cash flow of -$3.87 million.
| Operating Cash Flow | -26,000 |
| Capital Expenditures | -3.84M |
| Depreciation & Amortization | 12.76M |
| Net Borrowing | n/a |
| Free Cash Flow | -3.87M |
| FCF Per Share | -$0.37 |
Margins
Gross margin is 69.21%, with operating and profit margins of -11.61% and -13.64%.
| Gross Margin | 69.21% |
| Operating Margin | -11.61% |
| Pretax Margin | -9.73% |
| Profit Margin | -13.64% |
| EBITDA Margin | -7.35% |
| EBIT Margin | -11.61% |
| FCF Margin | n/a |
Dividends & Yields
Medifast does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.94% |
| Shareholder Yield | -0.94% |
| Earnings Yield | -30.38% |
| FCF Yield | -3.06% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Medifast has an Altman Z-Score of 3.55 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.55 |
| Piotroski F-Score | 2 |